ES
Eric Schmidt Cantor Fitzgerald Latest Price Targets & Analyst Ratings
Main Sector
Healthcare
Ratings Past Year
14
Avg Return
Past Year
Past Year
46%
Success Rate
Past Year
Past Year
0
%
Rating Distribution
Past Year
Positive
87.5%
Neutral
12.5%
Negative
0%
Past Week
Past Month
Past 3 Months
Past 6 Months
Past Year
All Time
Positive
Neutral
Negative
Large Cap
$10B to $200B
Mid Cap
$2B to $10B
Small Cap
$250M to $2B
Micro Cap
Under $250M
Healthcare
Healthcare
Biotechnology
Drug Manufacturers - General
| Stock | Rating | Price Target |
Upside Downside |
Ratings 1 Year |
Avg Return 1 Year |
Success Rate 1 Year | Date | |
|---|---|---|---|---|---|---|---|---|
|
Overweight
Maintained
| $74 |
287%
upside
| 3 | -18% |
0
%
| 17 Dec ‘25 2 months ago |
|
|
|
Overweight
Assumed
| – | – | 1 | -33% |
0
%
| 16 Oct ‘25 4 months ago |
|
|
|
Neutral
Assumed
| $88 |
23%
downside
| 1 | – |
–
| 9 Oct ‘25 5 months ago |
|
|
|
Overweight
Reiterated
| – | – | 3 | -1.3% |
0
%
| 8 Sep ‘25 6 months ago |
|
|
|
Overweight
Initiated
| – | – | 1 | +7.5% |
0
%
| 17 Jul ‘25 7 months ago |
|
|
|
Overweight
Reiterated
| $96 | – | 1 | +144% |
0
%
| 27 Jun ‘25 8 months ago |
|
|
|
Neutral
Reiterated
| – | – | 1 | -62% |
–
| 20 Jun ‘25 8 months ago |
|
|
|
Overweight
Reiterated
| – | – | 1 | +772% |
0
%
| 10 Jun ‘25 9 months ago |
|
|
|
Overweight
Reiterated
| – | – | 1 | +122% |
0
%
| 1 Apr ‘25 11 months ago |
|
|
|
Overweight
Initiated
| – | – | 1 | -56% |
0
%
| 21 Mar ‘25 11 months ago |
|
|
|
Overweight
Reiterated
| – | – | 1 | +514% |
0
%
| 20 Mar ‘25 11 months ago |
|
|
|
Overweight
Reiterated
| $13.01 |
34%
downside
| 1 | +51% |
0
%
| 13 Mar ‘25 1 year ago |
|